PDF HTML Untitled Untitled Untitled Untitled

PDF HTML

PDF HTML

PDF HTML

PDF HTML

PDF HTML

PDF HTML

PDF HTML

PDF HTML

PDF HTML Cover Letter

PDF HTML

PDF HTML Untitled Untitled Untitled Untitled Untitled Untitled

PDF HTML Fig1 Caligaris Fig.2 Caliga

PDF HTML

PDF HTML Untitled Cneo. Fig.1 Untitled Untitled Untitled

PDF HTML

PDF HTML Figure 1 Table 1

PDF HTML Kost Fig1 Kost Fig 2 Kost Fig3 Kost Fig 4 Kost Fig5 Kost fig 6

PDF HTML Fig.1b Fig.1c Fig.2a Fig.2b Fig.4 Fig.2c Fig.3 Tab.1 Tab.2 Tab.3 Tab.4 Fig1a

PDF HTML

PDF HTML

PDF HTML Table1

PDF HTML

PDF HTML

PDF HTML

PDF HTML Figure 1

PDF HTML

PDF HTML

PDF HTML Efremov 1 Efremov 2

PDF HTML

PDF HTML Characteristic of study group

PDF HTML

PDF HTML Bassan Fig.1 Bassan Fig.2 Bassan Fig.4 Fig.3

PDF HTML

PDF HTML

PDF HTML Untitled Untitled

PDF HTML figure 1 Untitled

PDF HTML

PDF HTML cover letter paper final AML

PDF HTML

PDF HTML

PDF HTML

PDF HTML

PDF HTML

PDF HTML Untitled

PDF HTML Figure 1: peripheral blood showing myeloblasts with auer rods Figure 2: CXR upon presentation to the hospital- no infiltrates nor consolidation changes Figure 3: CXR showing pulmonary infiltartes with consolidation Figure 4: CXR after starting steroid therapy- where the infiltrates have melted away Figure 5: barograph showing the rising TLC ad ANC values- associated with worsening symptoms and increasing pulmonary infiltrates in CXR

PDF HTML

PDF HTML

PDF HTML Table 1

PDF HTML INSTITUTE PUBLICATION COMMITTEE APPROVAL